THU0222 Multiswitching – from reference product etanercept to biosimilar and back again – real-world data from a clinic-wide multiswitch experience
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.2769
Abstract: Background The etanercept (ETN) biosimilar SB4 was introduced in Sweden in 2016 at a lower price than the reference product etanercept (RPE). Now the reverse is true, as the price of RPE dropped. Switching ETN-treated… read more here.
Keywords: back rpe; cohort; sb4; days 543 ... See more keywords